Nevirapine (Viramune) strengthens warning on liver, skin toxicities.
A recent letter to doctors strengthened the U.S. warnings and precautions on using this antiretroviral (which has been approved and in widespread use for years), due to serious complications in a small minority of patients; the point of the changes is to catch such problems and stop the drug in time. Patients obtaining refills or new prescriptions should in the future receive a "patient package insert," dated November 2000, based on the new warnings.
D004348:Drug Labeling; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D008099:Liver / Q000187:drug effects*; D008111:Liver Function Tests; D019829:Nevirapine / Q000009:adverse effects*; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects*; D012867:Skin / Q000187:drug effects*; D014481:United States; D014486:United States Food and Drug Administration
D018894:Reverse Transcriptase Inhibitors; D019829:Nevirapine